mammaglobin-A DNA vaccine / GSK, Washington University School of Medicine in St. Louis - LARVOL DELTA

Neoadjuvant endocrine treatment plus mammaglobin-A DNA vaccine induces antitumor immune responses in the primary tumor and peripheral blood of breast cancer patients: Insights from a phase 1b clinical trial. (PubMed, Cancer Immunol Res) - "In addition, post-vaccination tumor samples exhibited close spatial interactions between cytotoxic CD8+ T cells (CTL) and Mam-A+ tumor cells and between CTL and antigen-experienced CD4+ T cells. Together, these results suggest that Mam-A DNA vaccination elicits both systemic and intratumoral antitumor immune responses."

Journal • P1 data • Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • CD4 • CD8 • ER • Mammaglobin • PD-1 • SCGB2A2

Safety and Immune Response to a Mammaglobin-A DNA Vaccine In Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy (clinicaltrials.gov) - P1 | N=27 | Active, not recruiting | Sponsor: Washington University School of Medicine | Phase classification: P1b ➔ P1

Phase classification • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • HER-2 • SCGB2A2

Safety and Immune Response to a Mammaglobin-A DNA Vaccine In Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy (clinicaltrials.gov) - P1b | N=27 | Active, not recruiting | Sponsor: Washington University School of Medicine | Recruiting ➔ Active, not recruiting | N=56 ➔ 27 | Trial completion date: Jan 2029 ➔ Aug 2028 | Trial primary completion date: Jun 2024 ➔ Apr 2022

Enrollment change • Enrollment closed • Trial completion date • Trial primary completion date • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • HER-2 • SCGB2A2